Table 9.
Dose (mg/kg) | Route | Test | Duration of action | Comments | Reference |
0.01 | IM | Lap, TF | No effect | Dosed q12h for 72 h | 41 |
0.1 | IM | Lap, TF | Dosed q12h for 72 h. BW and food intake similar to saline treatment; TF increased latency | 41 | |
0.02-0.2 | IP | TF | 24 h at 0.2 mg/kg | Hyperalgesia at 0.01 mg/kg | 207 |
8 µg/kg | IV | TF | 4 h | 161 | |
0.4 | PO | Lap | 270-390 min | Observations limited to 390 min postoperative | 176 |
0.5-10 | PO-G | TF | 2 h at 5-10 mg/kg | 138 | |
0.5 | PO-G | HP | 3-5 h | 129 | |
0.1-0.4 | PO-J | Lap | Increased BW all treatment groups | 62 | |
0.5 | PO-J | HP | 1 h | 129 | |
0.5 | PO-J | Lap | Dosed q12h for 36 h. Not effective based on BW | 98 | |
0.5- 2.0 | PO-N | HP | 60-120 at 1 mg/kg | 92 | |
0.4 | PO-N | SX | No change in corticosterone; no change in activity 5h post op; BW loss less than control | 72 | |
0.3-3.0 | SC | HP, TF | ED50 0.4 mg/kg | 206 | |
0.03 | SC | Lap | Dosed q12h for 72 h. Decrease BW | 20 | |
0.03 | SC | PW | 24 h | Reduce RGS | 133 |
0.05 | SC | SX | Dosed q8-12h for 120 h. Improved gait | 27 | |
0.05 | SC | HP, SX, VF | No effect | Dosed q12h for 72 h | 34 |
0.05 | SC | HP | 1 h | 107 | |
0.05 | SC | SX | No effect | Dosed preoperative and 18 h postoperative supplemented with 0.25 mg/kg POJ | 117 |
0.05 | SC | HP | 3-5 h | 129 | |
0.05 | SC | 2 h | 138 | ||
0.05 | SC | HP | Dosed q12h for 60 h. PW latency increased; Minimal effect | 141 | |
0.05 | SC | Lap | 270-390 min postoperative | Observations limited to 390 min postoperative | 176 |
0.05 | SC | SX, VF, HP | Up to 96 h | Dosed q12h for 72 h. Reduced mechanical and thermal sensitivity. | 184 |
0.05 | SC | Lap | Lower ethogram score | 160 | |
0.1 | SC | FT | 6 h | 1 | |
0.1 | SC | HP | 30-240 min | 92 | |
0.1 | SC | Lap | Dosed q12h for 72 h. Lower ethogram score | 160 | |
0.25-0.1 | SC | VF | Increase threshold | 196 | |
0.2 | SC | PW, SX | PW no effect at 24h; no effect on vertical rises | 64 | |
0.5 | SC | SX | Increase corticosterone levels | 72 | |
0.5 | SC | SX | No effect | Supplemented with 0.25 mg/kg POJ | 117 |
0.5 | SC | HP, TF | 6-8 h | 66 | |
0.3 SRzp | SC | HP, SX, VF | No effect | 34 | |
0.65 SRzp | SC | HP | 4-48 h | 107 | |
1.2 SRzp | SC | HP, SX, VF | HP increase latency at 24h; VF no significant difference to baseline | 34 | |
1.2 SRzp | SC | SX, PW | Up to 48 h | Increase vertical rises compared with buprenorphine | 64 |
1.2 SRzp | SC | HP | 24-72h | 107 | |
1.2 SRzp | SC | SX, VF, HP | Up to 96 h | Reduced mechanical and thermal sensitivity. | 184 |
1.2 SRzp | SC | Lap | Dosed q12h for 72 h. Lower ethogram score | 160 | |
4.5 SRzp | SC | HP, SX, VF | HP increased latency at 24 h at 4.5 mg/kg; VF no effect; Sedative effect with 4.5 mg/kg | 34 |
Effects are based on a single dose of analgesic unless otherwise described in the comments.
PO-n = oral in Nutella; PO-J = oral in gelatin; PO-G = oral by gavage
SX = surgical model; Lap = Laparotomy
HP = hot plate assay; PW = paw withdrawal test; TF = tail-flick assay; VF = von Frey test
zP = manufactured by Zoopharm, Windsor, CO